SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions (INBS) is trending following news of a strategic manufacturing partnership aimed at significantly reducing production costs and expanding capacity, which has driven substantial intraday stock volatility. The community is actively discussing the stock's low float and high trading volume, fueling speculation about a potential short squeeze and anticipating further upward movement as it tests key resistance levels. This partnership is seen as a crucial step for scaling their fingerprint drug screening technology ahead of anticipated future market expansion.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in Boston, MA.

Ondas Holdings Inc

Ondas Holdings is gaining significant attention following its announcement of $10 million in new orders for autonomous systems, including counter-UAS and robotic ground solutions, signaling a strong demand in global defense and security. The community is buzzing with bullish sentiment, anticipating further growth as recent FCC actions against foreign drone imports create a compelling market opportunity for domestic manufacturers like Ondas, with many discussing a potential short squeeze.

ESH Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on November 17, 2021 and is headquartered in New York, NY.

ESH Acquisition Corp - Ordinary Shares - Class A

ESH Acquisition Corp (ESHA) is trending with high volatility, driven by its exceptionally low public float and significant insider ownership. The community is actively discussing its potential for a short squeeze, frequently drawing comparisons to other recent low-float SPACs that experienced rapid price surges. Sentiment remains bullish, fueled by speculation that its tight share structure could lead to further dramatic moves.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals (VNDA) is actively trending following the FDA approval of NEREUS, marking the first new motion sickness treatment in over 40 years. The community is highly focused on NEREUS's potential to address GLP-1 induced nausea, seeing this as a massive market opportunity and positioning VNDA as a compelling buyout target for larger pharmaceutical companies. This significant regulatory win, alongside a strong pipeline, is driving optimism for substantial future upside.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics is experiencing significant volatility following the FDA's Complete Response Letter for its relacorilant drug, which cited a need for more efficacy evidence despite the GRACE trial meeting its primary endpoint. This news has sparked a polarized debate, with many investors viewing the substantial stock drop as an overreaction and a prime "bargain biobuy" given the company's strong existing revenue and extensive pipeline. However, others remain cautious, calling it a "total reset" while some attribute parts of the decline to typical end-of-year tax-loss selling.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is experiencing a surge in conversation after significant insider buying, including notable purchases by CEO Elliott Hill and Apple CEO Tim Cook, signaled strong confidence in the company's prospects. This has sparked widespread bullish sentiment about a potential turnaround and a possible short squeeze, though some remain cautious, highlighting ongoing market challenges and competition.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP is trending as its community intensely debates future prospects amid persistent price challenges. Significant anticipation surrounds potential regulatory clarity from the "Clarity Act" and major developments like integrations with large retailers and payment networks. Despite widespread frustration over price action, many remain bullish, highlighting AMP's core utility in secure digital payments and its existing merchant adoption as crucial for eventual upside.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is trending as year-end tax loss selling and broader crypto market sentiment fuel a sharp divide among holders. The community actively debates whether current levels present a buying opportunity for a future rally or if further declines are imminent, reflecting a mix of long-term conviction and short-term volatility concerns.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

The iShares Silver Trust ($SLV) is trending amidst significant market volatility following repeated increases in margin requirements by the CME Group for precious metal futures. This has sparked intense debate, with many asserting that these actions are an attempt to suppress price discovery and protect short positions against strong industrial demand and potential global supply shifts, while others view the recent rally as unsustainable. The community is sharply divided between those accumulating on dips, expecting a substantial long-term rise, and those predicting a significant correction.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital is trending as the community discusses its strategic move to spin out its cloud business into a new entity, ChronoScale, while retaining significant ownership. This is largely viewed as a crucial step to eliminate perceived customer conflicts and allow APLD to focus as a pure-play AI data center infrastructure provider, aiming to unlock substantial value and attract higher valuations. High anticipation surrounds the upcoming earnings report, with many expecting strong financial performance and potential hyperscaler contract announcements to drive further momentum in the rapidly expanding AI sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is the Market Bullish or Bearish on Kazia Therapeutics Ltd?

Kazia Therapeutics Regains Full Nasdaq Listing Compliance

Kazia Therapeutics Regains Full Nasdaq Listing Compliance Kazia Therapeutics Regains Full Nasdaq Listing Compliance PR Newswire SYDNEY, Dec. 22, 2025 Restoration of Nasdaq compliance follows $50...

Kazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisib's Ability to Reinvigorate Anti-Tumor Immunity Across Multiple Advanced Breast Cancer Populations including TNBC and HER2+

Kazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisib's Ability to Reinvigorate Anti-Tumor Immunity Across Multiple Advanced Breast Cancer Populations...

What's Going On With Cancer Firm Kazia Therapeutics

Kazia announced a private placement of $50 million in equity securities. Proceeds will fund clinical development and extend cash runway.read more...

Kazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity Securities

Kazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity Securities Kazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity Securities PR Newswire...

<ul class="summary-bullets"><li>The patient remains on therapy and under active clinical monitoring, the company said.</li><li>In October, Kazia had announced that it observed an 86% reduction in tumor burden after only three weeks of treatment in the same patient.</li><li>Kazia also raised concerns on Tuesday regarding a potential suspension or delisting of its shares from the Nasdaq.</li></ul><p>Shares of cancer drug developer Kazia Therapeutics Limited (KZIA) were in the spotlight on Wednesday after the company said that a stage IV triple-negative breast cancer patient treated with a combination of its lead program Paxalisib with Pembrolizumab and standard chemotherapy has achieved an initial immune-complete response.</p><p>An immune-complete response means the complete disappearance of all signs of cancer following immunotherapy. It is also known as complete remission.</p><p>KZIA shares traded 42% higher on Wednesday morning at the time of writing.</p><h2 class="st-heading-2">Data And Takeaways</h2><p>As per Kazia, complete responses in stage IV metastatic TNBC are exceedingly uncommon and may suggest enhanced biological activity of the combination regimen, warranting continued follow-up.</p><p>In October, Kazia had announced that it observed an 86% reduction in tumor burden after only three weeks of treatment in the same patient. After about three months of therapy, a scan performed demonstrated complete metabolic resolution of all previously identified lesions, consistent with an initial immune-complete response, the company said.</p><p>The patient remains on therapy and under active clinical monitoring, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/kazia-therapeutics-achieves-initial-icr-immune-complete-response-in-metastatic-tnbc-and-delivers-q4-business-update-with-breakthroughs-across-breast-cancer-immuno-oncology-and-gbm-regulatory-strategy-302618635.html">added</a>. Kazia now plans to conduct a follow-up scan to confirm the initial scan.</p><h2 class="st-heading-2">Executive Commentary</h2><p>"Observing an initial complete response in a patient with metastatic triple-negative breast cancer is an extremely encouraging clinical finding," said CEO John Friend.</p><p>Paxalisib was licensed from Genentech in late 2016 and is being developed to treat multiple forms of cancer. The company now intends to request a meeting with the U.S. Food and Drug Administration to discuss the overall survival Paxalisib findings from its completed clinical studies and to discuss the elements needed for an application submission for Paxalisib in newly diagnosed glioblastoma.</p><h2 class="st-heading-2">Delisting Concerns</h2><p>Kazia on Tuesday also raised concerns about a potential suspension or delisting of its shares from Nasdaq, as it is not in compliance with certain listing rules. The company said it intends to request a hearing before a Nasdaq panel in a timely manner to stay any suspension or delisting action pending the outcome of the hearing.</p><p>The company is now also evaluating corporate and market-based options to regain compliance.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/KZIA">KZIA stock</a> jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.</p><figure class="image"><img style="aspect-ratio:585/56;" src="data:image/png;base64,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" width="585" height="56" alt="KZIA's Sentiment Meter and Message Volume as of 9:23 a.m. ET on Nov. 19, 2025 | Source: Stocktwits"><figcaption>KZIA's Sentiment Meter and Message Volume as of 9:23 a.m. ET on Nov. 19, 2025 | Source: Stocktwits</figcaption></figure><p>KZIA stock is down by 8% this year and by about 71% over the past 12 months.</p><p>Also See: <a href="https://stocktwits.com/news-articles/markets/equity/alkermes-to-acquire-avadel-for-up-to-2.37-billion-after-lundbeck-proposal/cLPoIyoREB2">Race For Avadel Heats Up: Alkermes Raises Offer To Secure $2.37B Deal After Lundbeck Challenge</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com</i></p>

Rising stock market chart on a trading board background.

KZIA Stock Soars After Stage IV Cancer Patient Shows Initial Complete Remission On Its Drug Combination

Kazia now plans to conduct a follow-up scan to confirm the initial scan. 

Equity

Kazia now plans to conduct a follow-up scan to confirm the initial scan. 


What Sparked Kazia Therapeutics' Over 51% After-Hours Surge?

Kazia Therapeutics jumped 51.74% in after-hours trading Tuesday after reporting a rare immune-complete response in a patient.read more...

Kazia Therapeutics Achieves Initial iCR (Immune-Complete Response) in Metastatic TNBC and Delivers Q4 Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology, and GBM Regulatory Strategy

Kazia Therapeutics Achieves Initial iCR (Immune-Complete Response) in Metastatic TNBC and Delivers Q4 Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology, and GBM Regulatory...

Kazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA initiative Project FrontRunner

Kazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA initiative Project FrontRunner Kazia Therapeutics to Request...

Kazia Therapeutics Ltd. is an oncology-focused biotechnology company, which engages in the business of pharmaceutical drug development. It focuses on its Paxalisib program, which is designed to treat brain cancer. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia.

KZIA
Kazia Therapeutics

Feed

News

Sentiment

Fundamentals

Info

Latest KZIA News

KZIAKazia Therapeutics